Drug Safety Legislation Unlikely, BIO CEO Greenwood Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Trade association's new chief sees no "great case for, or inclination on the part of the Senate leadership...to legislate on this topic." Upcoming Health Committee hearings may persuade senators to withdraw proposed legislation on drug safety issues, Greenwood says.
You may also be interested in...
Drug Safety To Be Topic Of Senate Health Hearings March 1 & 3
The Senate Health Committee will hold hearings on issues related to prescription drug safety March 1 and 3
FDA Drug Safety Reform Must Come From Outside Agency – Sen. Grassley
Oversight of the agency's drug safety functions is "going to have to be outside the FDA," Senate Finance Committee Chairman Grassley tells HHS Secretary Leavitt. Grassley still wants drug safety reviewers to have guaranteed independence from the Office of New Drugs, despite plans for a new Drug Safety Oversight Board.
FDA Drug Safety Oversight Board Will Include VA, Other Agencies
The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.